These authors contributed equally to this work.
Comparison of patient-reported outcome measures in multiple sclerosis
Article first published online: 7 FEB 2013
© 2013 John Wiley & Sons A/S
Acta Neurologica Scandinavica
Volume 128, Issue 2, pages 114–121, August 2013
How to Cite
Comparison of patient-reported outcome measures in multiple sclerosis. Acta Neurol Scand 2013: 128: 114‒121. © 2013 John Wiley & Sons A/S., , , , , .
- Issue published online: 9 JUL 2013
- Article first published online: 7 FEB 2013
- Manuscript Accepted: 14 DEC 2012
- Consortium Biopharma Neu2. Grant Number: 0315613
- German Ministry of Education and Research
- German Gemeinnützige Hertie-Stiftung. Grant Number: 1.01.1/08/117
- multiple sclerosis;
- quality of life
Patient-reported outcome measurements (PROMS) have been proposed sensitive outcome parameters in multiple sclerosis (MS). In this study, we assessed a German version of the Multiple Sclerosis Impact Scale (MSIS-29) and a revised version of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) in comparison with rater- and physician-based tools.
Consecutive MS patients (n = 117) of the MS outpatient unit were included. In addition to MSIS-29 and HAQUAMS, the following parameters were obtained: Expanded Disability Status Scale (EDSS) and modified Multiple Sclerosis Functional Composite (MSFC) [9-hole peg test (9HPT), 25-foot walk test and symbol digit modalities test]. We investigated validity, internal consistency and test–retest reliability as well as correlation between these measures.
Internal consistency (Cronbach's α ≤ 0.96) and test–retest coefficients (ICC ≤ 0.87) of both scales were high and satisfied psychometric standards. Convergent and discriminant validity was supported by direction, magnitude and pattern of correlation with other rater-based measures depending on the functional subdomain. Both MSIS-29 and HAQUAMS correlated with EDSS (ρ = 0.55 vs 0.62), but stronger correlation was found between MSIS-29 and HAQUAMS total score (ρ = 0.90). Both scales distinguished between patient groups of varied disease severity and cognitive impairment.
Patient-reported outcome measurements as MSIS-29 and HAQUAMS seem to be valid instruments to detect different impairment levels in comparison with traditional rater-based instruments like EDSS or MSFC.